ObsEva 
Welcome,         Profile    Billing    Logout  
 2 Products   3 Diseases  2 Products   4 Trials   178 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ebopiprant (OBE022) / Organon, Xoma
PROLONG, NCT03369262 / 2017-002579-25: PoC Study of OBE022 in Threatened Preterm Labour

Active, not recruiting
2a
115
Europe, RoW
OBE022, Placebos, Atosiban
ObsEva SA, SCOPE International AG, Iqvia Pty Ltd, Cytel Inc., PHINC DEVELOPMENT
Preterm Labor
07/20
08/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ebopiprant (OBE022) / Organon, Xoma
PROLONG, NCT03369262 / 2017-002579-25: PoC Study of OBE022 in Threatened Preterm Labour

Active, not recruiting
2a
115
Europe, RoW
OBE022, Placebos, Atosiban
ObsEva SA, SCOPE International AG, Iqvia Pty Ltd, Cytel Inc., PHINC DEVELOPMENT
Preterm Labor
07/20
08/22

Download Options